MiMedx Group, Inc. (MDXG) P/E Ratio History
Historical price-to-earnings valuation from 2014 to 2026
Loading P/E history...
MDXG Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, MiMedx Group, Inc. (MDXG) trades at a price-to-earnings ratio of 11.5x, with a stock price of $3.69 and trailing twelve-month earnings per share of $0.21.
The current P/E is 89% below its 5-year average of 108.0x. Over the past five years, MDXG's P/E has ranged from a low of 9.4x to a high of 1518.8x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, MDXG trades at a 48% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MDXG trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MDXG DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MDXG P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $787M | 14.5Lowest | 0.43Best | -35% | |
| $3B | 30.4 | 6.91 | -15%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MDXG Historical P/E Data (2014–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $3.95 | $0.20 | 19.3x | -89% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $6.77 | $0.32 | 20.9x | -88% |
| FY2025 Q3 | $6.98 | $0.27 | 25.5x | -85% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $6.11 | $0.22 | 27.9x | -84% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $7.60 | $0.27 | 27.7x | -84% |
| FY2024 Q4 | $9.62 | $0.29 | 33.6x | -80% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $5.91 | $0.59 | 10.1x | -94% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $6.93 | $0.59 | 11.8x | -93% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $7.70 | $0.46 | 16.6x | -90% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $8.77 | $0.36 | 24.5x | -86% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $7.29 | $0.00 | 1518.8x | +791% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $1.79 | $0.19 | 9.4x | -94% |
Average P/E for displayed period: 170.5x
See MDXG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDXG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDXG vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMDXG — Frequently Asked Questions
Quick answers to the most common questions about buying MDXG stock.
Is MDXG stock overvalued or undervalued?
MDXG trades at 11.5x P/E, below its 5-year average of 108.0x. At the 10th percentile of historical range, the stock is priced at a discount to its own history.
How does MDXG's valuation compare to peers?
MiMedx Group, Inc. P/E of 11.5x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MDXG's PEG ratio?
MDXG PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2014-2026.